It has previously been shown that patients with multiple duplications at the CDKN2A/ARF locus have poor survival, suggesting that multiple duplications, in combination with other genetic changes, have synergistic effects and negatively impact on BLCA prognosis (Berggren de Verdier et al., 2006); NLRP3 is the best-studied member of the NLR family, and it plays a crucial role in a variety of inflammatory pathologies (Inouye et al., 2018), and in an early tissue survey of NLRP3 expression, Kummer et al. found the presence of NLRP3 in the human bladder (Kummer et al., 2007). This evidence concerns the gene CDKN2A and bladder transitional cell carcinoma.